Antibody treatment for primary immunodeficiency that has not been treated
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 years old.
- You have a diagnosed primary immunodeficiency (a condition where your body doesn't make enough antibodies).
- You have never had immunoglobulin (antibody) replacement therapy before.
- Your IgG (antibody) level is 400 mg/dL or lower (a blood test will confirm).
- If you can become pregnant, you must agree to use effective birth control during the trial and for 30 days after the last dose.
- You do not have serious kidney problems, active infections, or certain heart or blood clot conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
This program lets people with primary immunodeficiency disease who were in an earlier study of this medicine continue receiving it if it is helping them. It is only for those who already took part in the earlier study and are still doing well on it.
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.